Business Wire

UAVITA-SYSTEMS

Share
UAVita Systems Together With Nova Poshta Successfully Completed the World’s First Civilian Long Range Intercity Autonomous Drone Flight

On July 29, 2021, UAVita Systems made history with a world aviation industry first – autonomous drone delivery of commercial packages between two major cities.

The Nova poshta commercial flight of UAVita’s DISCOVERY D-80 drone between Kyiv and Kharkiv, two major cities in Ukraine, was 480 km between takeoff and landing and carried a load of five parcels for delivery. The flight was fully autonomous from takeoff to waypoint navigation to landing and crossed several rivers, highways, avoiding populated areas, infrastructure objects and restricted airspace.

Airspace for the flight was reserved with local air traffic control, state air services, and several military authorities. The flight was operated by UAVita’s local Ukraine company, Aerodrone.

"The flight went exactly as planned," said Yuri Pederiy, CTO of UAVita. "Nova poshta was very pleased with the results."

DISCOVERY’s average air speed was 100 kph, with an altitude of 300 meters and total flight time was 4:45 hours a full hour ahead of schedule due to a tail wind.

"Commercial UAV with packages over the distance of 480 km is first in the world," said Oleksandr Bulba, CEO of Nova poshta. "Beside Nova poshta there is no other logistic company that has completed this flight. Our plans are to shorten the flight time to 3 hours to cover the same distance and scale up package drone delivery and make it more affordable to our customers."

Nova poshta’s and UAVita’s next autonomous parcel delivery test flight will take place in late August between the cities of Kyiv and L’viv. The target is to eventually reduce the flight time even further by deploying UAVita’s next generation drones.

“Most conventional drone deliveries are focused on last mile delivery within few kilometers. UAVita took the leap and developed intercity package delivery. This capability adds more flexibility to shipping urgent and high value packages especially to remote locations that are difficult to reach by ground transportation. Combining last mile and intercity delivery can further automate the logistic chain and optimize the operating costs for the courier companies,” explained Pederiy.

Nova poshta is a private Ukrainian postal and courier company and the leader of the logistics in the Ukraine market that provides express delivery of documents, freight and parcels for individuals and businesses. The company delivers shipments through more than 8500 branches, 6700 lockers, and to the customer’s physical address. In 2020 Nova poshta delivered over 318 million shipments throughout Ukraine.

UAVita is a designer, manufacturer and integrator of purpose-built fixed wing high payload autonomous drones. UAVita’s DISCOVERY D-80 drone was recently awarded top place in the Krypto Labs Drone X Challenge 2020 . The DISCOVERY is an industry leading drone with a maximum payload of 80 kg and non-stop flight time of 10 hours or 1000 km. UAVita is set to launch their next generation fixed wing drone that has a maximum payload of 340 kg and non-stop flight time of 30 hours or 4500 km.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye